{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:48Z","timestamp":1792785948511,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","funder":[{"name":"UK Health Security Agency","id":[{"id":"https:\/\/ror.org\/018h10037","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["N01-CP-11005"],"award-info":[{"award-number":["N01-CP-11005"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000124","name":"Office of Research on Women's Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human papillomavirus (HPV) variants are classified into lineages and sublineages based upon their genome sequence, but the impact of variation on the function of encoded proteins is unclear. We used a global panel of natural infection sera and relational antigenic maps to assess HPV33 and HPV45 neutralizing antibody specificity. HPV33 A2, A3, B, and C variants were spatially resolved approximately 5-fold distant from the A1 reference, while HPV45 variants were resolved within approximately 2-fold, with differences mapped to residues on the capsid surface. These data inform the degree of lineage and sublineage specificity within the natural infection humoral immune response to oncogenic HPV.<\/jats:p>","DOI":"10.1093\/infdis\/jiag487","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:01:51Z","timestamp":1790164911000},"source":"Crossref","is-referenced-by-count":0,"title":["HPV33 and HPV45 Sublineage Antigenicity Defined by Neutralizing Antibodies Elicited During Natural Infection"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5280-185X","authenticated-orcid":false,"given":"Kazutomo","family":"Yokoya","sequence":"first","affiliation":[{"name":"Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Panwar","sequence":"additional","affiliation":[{"name":"Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0428-3116","authenticated-orcid":false,"given":"Vanessa","family":"Tenet","sequence":"additional","affiliation":[{"name":"Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer\/World Health Organization , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-1015","authenticated-orcid":false,"given":"Rana","family":"Hussain","sequence":"additional","affiliation":[{"name":"Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomeno","family":"Coelho da Silva","sequence":"additional","affiliation":[{"name":"Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-0106","authenticated-orcid":false,"given":"Lisa","family":"Mirabello","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Schiller","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary M","family":"Clifford","sequence":"additional","affiliation":[{"name":"Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer\/World Health Organization , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-6215","authenticated-orcid":false,"given":"Simon","family":"Beddows","sequence":"additional","affiliation":[{"name":"Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026100807220155200_jiag487-B1","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2026100807220155200_jiag487-B2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.virol.2013.07.018","article-title":"Human papillomavirus genome variants","volume":"445","author":"Burk","year":"2013","journal-title":"Virology"},{"key":"2026100807220155200_jiag487-B3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/molbev\/msw214","article-title":"Transmission between archaic and modern human ancestors during the evolution of the oncogenic human papillomavirus 16","volume":"34","author":"Pimenoff","year":"2017","journal-title":"Mol Biol Evol"},{"key":"2026100807220155200_jiag487-B4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.virol.2013.05.038","article-title":"The papillomavirus major capsid protein L1","volume":"445","author":"Buck","year":"2013","journal-title":"Virology"},{"key":"2026100807220155200_jiag487-B5","doi-asserted-by":"crossref","first-page":"31803","DOI":"10.1074\/jbc.M706380200","article-title":"Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies","volume":"282","author":"Bishop","year":"2007","journal-title":"J Biol Chem"},{"key":"2026100807220155200_jiag487-B6","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026100807220155200_jiag487-B7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/sextrans-2024-056296","article-title":"Systematic review and meta-analysis of the association between naturally induced IgG, IgM and neutralising antibodies to HPV16 and newly detected cervical HPV16 infection outcomes","volume":"101","author":"Trevisan","year":"2025","journal-title":"Sex Transm Infect"},{"key":"2026100807220155200_jiag487-B8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/s41467-024-45807-w","article-title":"Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection","volume":"15","author":"Kamuyu","year":"2024","journal-title":"Nat Commun"},{"key":"2026100807220155200_jiag487-B9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.virol.2013.10.033","article-title":"Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer","volume":"448","author":"Chen","year":"2014","journal-title":"Virology"},{"key":"2026100807220155200_jiag487-B10","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/infdis\/jiz401","article-title":"Sensitivity of human papillomavirus (HPV) lineage and sublineage variant pseudoviruses to neutralization by nonavalent vaccine antibodies","volume":"220","author":"Godi","year":"2019","journal-title":"J Infect Dis"},{"key":"2026100807220155200_jiag487-B11","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01236-20","article-title":"Comprehensive assessment of the antigenic impact of human papillomavirus lineage variation on recognition by neutralizing monoclonal antibodies raised against lineage A major capsid proteins of vaccine-related genotypes","volume":"94","author":"Godi","year":"2020","journal-title":"J Virol"},{"key":"2026100807220155200_jiag487-B12","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1099\/jgv.0.000829","article-title":"Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies","volume":"98","author":"Godi","year":"2017","journal-title":"J Gen Virol"},{"key":"2026100807220155200_jiag487-B13","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1128\/JVI.02859-15","article-title":"Naturally occurring major and minor capsid protein variants of human papillomavirus 45 (HPV45): differential recognition by cross-neutralizing antibodies generated by HPV vaccines","volume":"90","author":"Godi","year":"2015","journal-title":"J Virol"},{"key":"2026100807220155200_jiag487-B14","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1093\/infdis\/jiaf502","article-title":"Profiling human papillomavirus lineage-specific capsid antigenicity with geographically diverse natural infection antibodies","volume":"233","author":"Panwar","year":"2026","journal-title":"J Infect Dis"},{"key":"2026100807220155200_jiag487-B15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41541-024-00896-y","article-title":"Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trial","volume":"9","author":"Shing","year":"2024","journal-title":"NPJ Vaccines"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag487\/71403450\/jiag487.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag487\/71403450\/jiag487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:22:12Z","timestamp":1791458532000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag487\/8836684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag487","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"article-number":"jiag487"}}